SARTF (Sartorius AG) Total Equity: $4,498 Mil (As of Mar. 2026)


SARTF Sartorius AG SARTF
85 GF Score
Price $192.43
GF Value $226.12
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sartorius AG Total Equity?

Sartorius AG SARTF -1.83% 85 Total Equity is $4,498 Mil as of Mar. 2026. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $226.12 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Sartorius AG's total equity for the quarter that ended in Mar. 2026 was $4,498 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sartorius AG Total Equity Historical Data

* Premium members only.

The historical data trend for Sartorius AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius AG Total Equity Chart

Sartorius AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,943.73 2,816.63 3,007.63 4,081.47 4,528.45

Sartorius AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,148.87 4,376.36 4,475.94 4,528.45 4,497.92
SARTF
85GF Score
Sartorius AG SARTF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sartorius AG's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=11378.454-6850
=4,528

Sartorius AG's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=11412.832-6914.913
=4,498

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $4,498 Mil mean?
Sartorius AG (SARTF) has a Total Equity of $4,498 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Sartorius AG and its competitors.
Is Sartorius AG's Total Equity too high?
Sartorius AG's current Total Equity is $4,498 Mil. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Total Equity compare to ISRG and BDX?
Sartorius AG's Total Equity of $4,498 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sartorius AG and its competitors. Sartorius AG's current Total Equity is $4,498 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $226.12, compared to a current price of $192.43 — trading 14.9% below its estimated fair value. The current Total Equity is $4,498 Mil. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Total Equity is $4,498 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius AG (SARTF) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of $192.43 is trading 14.9% below its estimated GF Value™ of $226.12. GuruFocus considers Sartorius AG to be Modestly Undervalued.

Key valuation signals for SARTF:

  • Total Equity: $4,498 Mil
  • GF Value™: $226.12 vs. price of $192.43 (14.9% below fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score

Get the complete analysis for SARTF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$192.43
Price
$226.12
GF Value